Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory Innovations.
ACS Med Chem Lett October 9, 2025 DOI: 10.1021/acsmedchemlett.5c00597 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psilocin prodrugs |
| Topics | Psychedelic-assisted therapy |
| Key findings | Recent patents describe complementary strategies—novel psilocin prodrugs, digital cognitive state monitoring, and combining neuroplastogen drugs with transcranial electrical stimulation—that converge on a precision framework for treating neuropsychiatric disorders. |
Abstract
Recent patents disclose complementary strategies to optimize psychedelic-assisted therapy. Novel psilocin prodrugs improve pharmacokinetics and stability, while digital systems enable cognitive state monitoring during treatment. Parallel advances in combining neuroplastogen drugs with transcranial electrical stimulation highlight a model-driven approach to enhance and personalize neural plasticity. Together, these innovations converge on a precision framework for treating neuropsychiatric disorders.